



LUNGevity Foundation Bios

LUNGevity Foundation Board of Directors

Andrea Stern Ferris, President and Chairman of the Board

Andrea Ferris became deeply committed to finding a way to increase survivorship of lung cancer after losing her mother, Patricia Stern, to the disease. Along with her siblings and father, she co-founded Protect Your Lungs, an organization dedicated to research into the early detection of lung cancer, and served as Executive Director until its merger with LUNGevity Foundation in 2010. Prior to that she held a number of management positions at Decision Lens, Johnson & Johnson, and Coopers & Lybrand. Andrea holds an MBA from University of Pennsylvania's Wharton School of Business with concentrations in finance and Latin American studies and a BS in Economics with concentrations in accounting, decision sciences, and finance.

Peter Babej

Peter Babej is Global Co-Head of Financial Institutions Group at Citigroup Global Markets Inc. Previously, Peter served as Co-Head of Financial Institutions – Americas at Deutsche Bank, and as a Managing Director at Lazard. Over the course of his career, Peter has advised many leading companies across the financial and public sectors worldwide with respect to both mergers and acquisitions and financing. Peter holds a BA from the Woodrow Wilson School of Princeton University as well as a JD and PhD from Harvard University.

Susan Bersh

Sue Bersh is Vice President, Communications, with AMLI Residential, an owner, developer, and manager of luxury apartment communities across the country, where she has worked for over 24 years. Sue lost her grandmother to lung cancer many years ago and, in 2008, she lost one of her best friends, Elyse Bernstein Keefe, to the disease. She is determined to make a difference in funding hope and providing support for lung cancer patients and their loved ones in their memory. She has a BS in Economics from the University of Illinois.

Dennis Bookshester

Dennis Bookshester, an accomplished businessman who has held prestigious leadership positions in the retail industry, including President and CEO of Fruit of the Loom, President and CEO of Zale Corporation, and Vice Chairman of Carson Pirie Scott & Company, joined LUNGevity to help broaden its reach and impact. Dennis has also advised many leading companies, such as Playboy Enterprises and The Turtle Wax, Inc., as a member of the board and trustee, and has shared his knowledge with other nonprofits, including The United Way, the Chicago Chamber of Commerce, and United Cerebral Palsy of Greater Chicago. Dennis, currently an independent investor and consultant, was diagnosed with lung cancer in 2013 and is a strong proponent for the early detection of the disease.

Patrick Chen

Patrick Chen is the CEO of JD Capital USA. JD Capital is China's largest private equity firm, and one of Patrick's goals is to introduce LUNGevity to China. Patrick was formerly a senior executive at Industrial and Commercial Bank of China (ICBC), overseeing the bank's global M&A activities. He has also worked for Shanghai International Securities, co-heading its international division. Patrick has master's degrees from Indiana University and the Graduate School of People's Bank of China. Patrick lost his mother to lung cancer.



Lynne Doughtie

Lynne Doughtie, Chairman and Chief Executive Officer of KPMG LLP, one of the world's leading professional services firms, recently lost her mother to lung cancer and is passionate about wanting to make a difference in changing outcomes for all those affected by the disease. Lynne is a Governing Board member for the Center for Audit Quality and a member of The Committee of 200. She also serves as a board member for both NAF and the Partnership for New York City. Lynne has received numerous recognitions including being named one of: *Fortune's* Most Powerful Women in Business, *Accounting Today* magazine's Top 100 Most Influential People, and the National Association of Corporate Directors' 100 most influential people in the boardroom. Lynne also was named the 2015 "Woman of Achievement" by the National Association for Female Executives.

Chris Olivier

Chris Olivier is an entrepreneur with extensive consumer marketing and general management experience, working in operating roles in both private equity and non-profit arenas. Currently, Chris is a principal in Craft Catalyst, a beverage brand accelerator helping emerging brands manage their growth. Chris served as an active board member of Take Aim At Cancer, a non-profit focused on raising funds and awareness for targeted cancer therapy, which joined with LUNGevity in early 2013.

Charles Rudin

Dr. Charles Rudin is Chairman of LUNGevity's Scientific Advisory Board and Chief of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center. Dr. Rudin directs a broad research program of therapeutic research with the ultimate goal of improving the outcomes for patients with lung cancer. His research includes laboratory-based investigations to identify and test novel treatment approaches to lung cancer, early-phase clinical trials to bring these ideas to the clinic, and later-phase studies to establish the efficacy of these new approaches. He also co-chairs the Eastern Cooperative Oncology Group Thoracic Committee, and is a member of the National Cancer Institute Thoracic Malignancies Steering Committee.

Jerry Sorkin (deceased)

Jerry Sorkin served as Vice Chair of the LUNGevity Board of Directors from 2010 through his passing in 2016. He was diagnosed with stage IV lung cancer in August 2007. He began working with LUNGevity as a member of the communications committee and the strategic planning task force and joined the Board of Directors in October 2009. For more than a decade, Jerry was part of the Corporate Executive Board's leadership team. He earned a JD from Harvard Law School and a BA from Yale College.

Alexander Stern

Alexander Stern has served as Chief Operating Officer of Lazard Ltd since November 2008, and has been the Chief Executive Office of Financial Advisory since April 2015. He has served as a Managing Director since January 2002 and as the Firm's Global Head of Strategy since February 2006. Alex initially joined Lazard in 1994. As a Managing Director in Lazard's Financial Advisory Group, he has worked on a broad array of assignments as a member of the Technology, Media and Telecommunications Group for such clients as IBM, Nextel, MCI, 360networks, Rural Cellular, Asia Global Crossing, SBC Communications, Cap Gemini, and Lotus.



Andrew Stern

Andrew Stern has spent his entire career focused on early-stage company development, financing, and operations. At present, Andy is a Founder and Managing Partner at Five Points Partners, LLC, a New York-based business catalyst focused on building and operating a portfolio of companies in a variety of industries, including finance, technology, and multi-unit franchise concepts. Prior to joining FPP, Andy founded AMT Partners, an investment group focused on personal private equity investments. Previously, Andy was a Managing Director and Entrepreneur-In-Residence of idealab!, where he managed portfolio company development, which included idea vetting, strategic planning, and technical development.

Paul G. Stern

Paul Stern co-founded Protect Your Lungs with his children after his wife of 43 years, Patricia, died of lung cancer. Paul has been a leader in the business and non-profit community for more than four decades. He is the former Presiding Director of Dow Chemical Company and served as chair of the Governance Committee and as a member of the Audit and Executive Committees. He was also a Director of Whirlpool Corporation, where he chaired the Human Resources Committee and was a member of the Governance Committee of the Board. Paul is the chairman of the National Symphony Orchestra and is involved with many other philanthropic boards.

Marc Swerdlow

Marc Swerdlow joined LUNGevity as a volunteer in 2005 after his father lost his battle with lung cancer. Marc's mother is a lung cancer survivor. Marc is a principal and the Chief Operating Office at Magellan Investment Partners LLC. Prior to joining Magellan, Marc was Executive Vice President and General Counsel and a member of the Executive Committee at Waterton Associates LLC. He has also been a Senior Investment Manager with GE Capital Real Estate, where he was responsible for structuring and closing structured debt and joint venture transactions, as well as a Senior Vice President with Heitman Advisory Corporation.

LUNgevity Foundation Scientific Advisory Board

Charles M. Rudin, MD, PhD, Chairman of LUNgevity's Scientific Advisory Board

Memorial Sloan Kettering Cancer Center

Professor and Chief, Thoracic Oncology Service

Dr. Rudin directs a broad research program of therapeutic research with the ultimate goal of improving the outcome for patients with lung cancer. His research includes laboratory-based investigations to identify and test novel treatment approaches to lung cancer, early-phase clinical trials to bring these ideas to the clinic, and later-phase studies to establish the efficacy of these new approaches. He is interested in small cell and non-small cell lung cancers. Some of the strategies his group has explored both in the laboratory and in the clinic include turning back on genes silenced in cancer, re-activating cancer cell death pathways, and treating lung cancer with a cancer-specific virus. Dr. Rudin also co-chairs the Eastern Cooperative Oncology Group Thoracic Committee, and is a member of the National Cancer Institute Thoracic Malignancies Steering Committee.

Scott J. Antonia, MD, PhD

Moffitt Cancer Center

Chair, Department of Thoracic Surgery

Dr. Antonia's work focuses on translational research. Using his molecular biology and cellular background in the development of immunotherapeutic strategies for the treatment of cancer patients, he has developed strategies designed to thwart the immunosuppressive mechanisms used by tumors to evade T-cell mediated rejection. His clinical interests focus on immunotherapy and immunobiology, in particular, gene-modified tumor cell vaccine trials at both pre-clinical and clinical stages. He has designed and conducted numerous cutting-edge studies with novel immunotherapeutics and has two patents for technology he has developed. He has been awarded a K24 grant from the National Cancer Institute to support his clinical research and is the principal investigator for a Thoracic SPORE project. Dr. Antonia is also conducting several ongoing investigator-initiated clinical trials testing novel tumor vaccines and tumor vaccine augmentation strategies for the treatment of various cancers. Dr. Antonia also serves as chairman of Moffitt's Scientific Review Committee and medical director of the Tumor Vaccine Production Facility at Moffitt. He was named the Moffitt Physician of the Year in 2005 and Mentor of the Year in 2008. Dr. Antonia has published papers in several peer-reviewed journals, including *Science*, *Clinical Cancer Research*, *Current Opinions in Oncology*, and *Cancer Research*. In 2014, he was recognized as the "Most Cited Faculty" during the Moffitt Faculty Appreciation/Recognition Reception. In 2015, he was inducted into the National Academy of Inventors.

Philip D. Bonomi, MD

Rush University Medical Center

Alice Pirie Wirtz Professor of Medical Oncology

Director, Division of Hematology-Oncology

Dr. Bonomi has been involved in lung cancer research for almost three decades. He is a member of the International Association for the Study of Lung Cancer and has served as the Chairman of the Thoracic Committee for the Eastern Cooperative Oncology Group. His primary area of interest is within the field of thoracic and cardiothoracic oncology, with his specialties being in lung cancer and mesothelioma. The majority of Dr. Bonomi's research interest is in the field of lung cancer treatment and detection. His most recent research has centered on the study of new chemotherapeutic agents for multi-modality therapies in the treatment of small-cell lung cancer. Dr. Bonomi has authored or co-authored more than 150 journal articles, primarily in the field of small cell lung cancer detection and survival-rate improvements.

Julie R. Brahmer, MD

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Director, Thoracic Oncology Program

Associate Professor of Oncology

Interim Co-Director, Upper Aerodigestive (UAD) Program

Interim Director, Johns Hopkins Kimmel Cancer Center at Bayview

Dr. Brahmer is an international leader in the field of immunotherapy for patients with lung cancer. She is the author of more than 90 scholarly articles and has spoken on immunology at events nationwide. She was named director of the Thoracic Oncology Program at the Kimmel Center at Johns Hopkins University in January 2015. Dr. Brahmer is best known for her research related to the phase I trial of the PD-1 inhibitor nivolumab, an immunotherapy drug that has shown remarkable promise for lung cancer patients. She serves on the board of several national foundations.

David P. Carbone, MD, PhD

The Ohio State University

Professor, Division of Medical Oncology

Barbara J. Bonner Chair in Lung Cancer Research

Director of the Thoracic Oncology Center

President, International Association for the Study of Lung Cancer (IASLC)

Dr. Carbone's research interests, grant support, and publications have been focused on lung cancer, specifically on proteomic and expression array signature development, lung cancer genetics, cancer immunotherapy, tumor-associated immunosuppression mechanisms, and gene therapy. Recent research directions include development of molecular biomarkers to guide patient management and therapy, and molecular profiling of lung cancers and preneoplasias to guide the development of novel therapeutics, especially the use of mass spectrometry-based proteomics. He has over 200 peer-reviewed publications, books, and review articles, has served on several NCI grant review panels, and has had continuous NCI funding since early in his career. He has served on organizing committees for both ASCO and AACR and the Board of Scientific Counselors for the NCI, and is currently Chair of the Lung Biology subcommittee for the Eastern Cooperative Oncology Group and President-Elect of the International Association for the Study of Lung Cancer (IASLC).

Suzanne E. Dahlberg, PhD

Dana-Farber Cancer Institute

Harvard T.H. Chan School of Public Health

Senior Research Scientist

Dr. Dahlberg's primary research focuses on clinical and translational studies in lung cancer as the primary statistician for both the ECOG-ACRIN Thoracic Committee and the Thoracic Oncology Program at Dana-Farber Cancer Institute. In those roles, she leads the design, development, monitoring, analysis and reporting of these groups' phase I-III clinical trials, as well as their corresponding correlative and laboratory studies. She is currently a member of the NCI Thoracic Malignancy Steering Committee, the NCTN Core Correlative Sciences Committee, and the Nature journals statistical consultants group. She is also the recipient of the 2016 ECOG-ACRIN Young Investigator Award.

Jessica S. Donington, MD, MSCr

NYU School of Medicine

Associate Professor, Cardiothoracic Surgery

Director, Thoracic Oncology Translational Laboratory

Chief, General Thoracic Surgery, Bellevue Hospital

Dr. Donington's clinical interests focus on the early diagnosis and treatment of non-small cell lung cancer. Her areas of expertise include the use of multimodality therapy for thoracic malignancies, treatment options for high-risk patients with early-stage lung cancer, and lung cancer in women. She is the surgical chair for the thoracic malignancy group of NRG Oncology Group and the president of Women in Thoracic Surgery.

Steven M. Dubinett, MD

David Geffen School of Medicine at UCLA

Chief, Division of Pulmonary and Critical Care Medicine

Senior Associate Dean for Translational Research

Associate Vice Chancellor for Research

Director, Clinical and Translational Science Institute (CTSI)

Dr. Dubinett has extensive experience in translational investigation, academic administration, mentorship, and peer review. Building on original discoveries relevant to inflammation in the pathogenesis of lung cancer, he has developed a translational research program which now utilizes these laboratory-based discoveries in the translational research and clinical environment. His studies focus on the microenvironment, inflammation, and epithelial mesenchymal transition (EMT) in the pathogenesis of lung cancer. He serves as the Chair of the Research Evaluation Panel for biospecimen utilization for the American College of Radiology Imaging Network / National Lung Screening Trial (ACRIN / NLST). He also serves on the NCI Thoracic Malignancy Steering Committee as a Translational Science Representative. Dr. Dubinett has trained more than 30 graduate students, post-doctoral fellows, and junior faculty, nearly all of whom have continued in academic careers.

Edward W. Gabrielson, MD

Johns Hopkins University School of Medicine

Professor of Pathology and Oncology

Dr. Gabrielson specializes in molecular pathology, with particular emphasis on the pathology of lung, breast, and esophageal cancers. His research emphasizes aspects that have potential clinical significance. Current areas of emphasis include molecular classification of cancers, genetic instability in cancer, and functional changes in cancers related to cell-cell interactions and cellular metabolism. Dr. Gabrielson serves as co-director of the graduate program in pathology. He has authored or co-authored numerous peer-reviewed publications.

Edward B. Garon, MD

Jonsson Comprehensive Cancer Center at UCLA:

Director of the Thoracic Oncology Program

David Geffen School of Medicine at UCLA:

Associate Professor of Medicine

After growing up in Minneapolis, he earned a bachelor's degree in biology at the Massachusetts Institute of Technology. His MD degree is from Washington University in St. Louis. He performed his internship and residency at the University of Chicago.

After a chief residency at Cook County Hospital in Chicago, Dr Garon was a fellow in hematology and oncology at UCLA. He has remained at UCLA ever since and is currently an Associate Professor of Medicine in the Division of Hematology-Oncology at the David Geffen School of Medicine at UCLA. He also received a Master's degree in clinical investigation from UCLA.

Dr Garon has been the principal investigator of peer-reviewed grants from various funding organizations, including the National Cancer Institute. His focus is on clinical research and biomarker development. He has served as the principal investigator on national and international phase I, II, and III clinical trials, including trials that have led to the approval of multiple drugs, among them the non-small cell lung cancer drugs ramucirumab (Cyramza®) and the immunotherapy pembrolizumab (Keytruda®), along with a companion diagnostic.

John V. Heymach, MD, PhD

The University of Texas MD Anderson Cancer Center

Professor and Chairman, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine

Dr. Heymach's research focuses on investigating mechanisms of therapeutic resistance, understanding the regulation of angiogenesis in lung cancer, and developing biomarkers for selecting patients most likely to benefit from targeted agents. Dr. Heymach has led a number of phase I/II clinical trials in non-small cell lung cancer and currently serves as the principal investigator on the BATTLE-frontline trial using novel combinations of targeted agents as frontline therapy for non-small cell lung cancer patients. His work has been extensively published in prominent peer-reviewed journals.

Robert L. Keith, MD

University of Colorado, Denver

Professor of Medicine and Cancer Biology

Denver VAMC:

Associate Chief of Staff-Research

Dr. Keith's research interests focus on the early detection and prevention of lung cancer. Specifically, his team is examining prostaglandin manipulation and PPAR gamma agonists in pre-clinical models of non-small cell lung cancer, including genetically modified mice. An NCI-sponsored human trial is currently in progress, and future trials are in the planning stage. His team's chemoprevention trials include performing fluorescence bronchoscopy, which allows for improved detection of pre-malignant central airway lesions, and they are better characterizing these lesions in terms of lung cancer biomarker discovery and validation.

Pierre P. Massion, MD

Vanderbilt-Ingram Cancer Center

Cornelius Vanderbilt Chair in Medicine

Professor of Medicine and Cancer Biology

Director, Thoracic Program

Dr. Massion is committed to pursuing innovative strategies to deepen the understanding of lung cancer development and progression. His laboratory applies novel genomic and proteomic technologies to biological specimens to address questions related to the identification and validation of molecular determinants of disease diagnosis, progression, prognosis, and intermediate endpoint biomarkers of response to chemopreventive strategies. In addition to having published more than 80 times, Dr. Massion has mentored more than 19 postdoctoral fellows, 100 graduate students, and 20 undergraduate students.

Paul K. Paik, MD

Memorial Sloan Kettering Cancer Center

Assistant Attending Physician

Clinical Director, Thoracic Oncology Service

Dr. Paik specializes in the treatment of lung cancers. He has served as a member of The Cancer Genome Atlas Squamous Cell Lung Cancer Working Group, dovetailing with his research focus on squamous cell lung cancer, targeted therapeutics, and translational therapies aimed at the metastatic process.

Lawrence H. Schwartz, MD

Columbia University Medical Center:

James Picker Professor and Chairman, Department of Radiology

NewYork-Presbyterian/Columbia University Medical Center:

Radiologist-in-Chief

Dr. Schwartz is internationally recognized for the innovative application of new technology in imaging to improve both clinical care and drug discovery. Renowned in the field of oncologic imaging, he is an authority on the development and validation of imaging biomarkers. His research has focused on new computational and functional techniques that utilize physiologic imaging and advanced image processing to assess and correlate imaging characteristics with molecular features of disease processes, in particular solid tumors of the chest, abdomen, and pelvis. At Memorial Sloan Kettering Cancer Center, Dr. Schwartz founded the Laboratory for Computational Image Analysis, which focuses on advanced image processing to quantitatively assess therapeutic efficacy in clinical care and drug discovery.

Lecia V. Sequist, MD, MPH

Harvard Medical School:

The Landry Family Associate Professor of Medicine

Massachusetts General Hospital Cancer Center

Dr. Sequist's research focuses on studying novel targets for lung cancer treatment, especially in patients with epidermal growth factor receptor (EGFR) mutations and other driver oncogenes. She also studies the changes that occur in cancers at the time of acquired drug resistance and the significance of tumor cells circulating in the bloodstream (circulating tumor cells, or CTCs). She aims to develop treatment algorithms for lung cancer that are more personalized than current strategies, utilizing targeted therapies specific to the patients' cancer genotypes, and understanding how this may change over the courses of the disease.

Steven J. Skates, PhD

Harvard Medical School and Massachusetts General Hospital

Associate Professor

Dr. Skates developed the Risk of Ovarian Cancer Algorithm (ROCA) along with Robert C. Knapp, MD, professor emeritus, Harvard Medical School. Dr. Skates and his colleagues applied the algorithm to blood samples in an ovarian cancer screening study conducted by Ian Jacobs, MD, of St. Bartholomew's Hospital, London. Dr. Skates received his Bachelor of Science degree in Mathematics at the University of Western Australia, Perth, Australia. He completed his PhD in Biostatistics at the University of Chicago in 1987.

Avrum E. Spira, MD, MSci

Boston University

Director of the Boston University Cancer Center

Professor of Medicine, Pathology and Bioinformatics

Alexander Graham Bell Professor in Healthcare Entrepreneurship

Chief, Section of Computational Biomedicine

Dr. Spira's laboratory research interests focus on applying high-throughput genomic and bioinformatics tools to the translational study of lung cancer and Chronic Obstructive Lung Disease (COPD). The primary research focus of the lab is to determine how cigarette smoking affects cell gene expression and to use this information to develop a biomarker for lung cancer that can identify that subset of smokers who have, or are at risk for developing, lung cancer.

Anil Vachani, MD

University of Pennsylvania

Associate Professor of Medicine, Pulmonary and Critical Care Division

Director of the Lung Nodule Program

Co-Director of the Lung Cancer Screening Program

Director of Bronchoscopy at the Philadelphia VA Medical Center

Dr. Vachani's research is focused on the discovery and validation of early detection and treatment prediction biomarkers for lung cancer and mesothelioma. Additional areas of research include studies on the measurement of biomarkers from circulating tumor cells and circulating free DNA. Finally, he is conducting studies on population level uptake of genomic and genetic technologies for treatment decisions in lung cancer using cancer registry and claims data.